CROSS COUNTRY HEALTHCARE INC (CCRN) Fundamental Analysis & Valuation
NASDAQ:CCRN • US2274831047
Current stock price
9.86 USD
-0.03 (-0.3%)
At close:
9.86 USD
0 (0%)
After Hours:
This CCRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CCRN Profitability Analysis
1.1 Basic Checks
- In the past year CCRN was profitable.
- CCRN had a positive operating cash flow in the past year.
- In multiple years CCRN reported negative net income over the last 5 years.
- Of the past 5 years CCRN 4 years had a positive operating cash flow.
1.2 Ratios
- CCRN has a worse Return On Assets (-21.13%) than 80.00% of its industry peers.
- With a Return On Equity value of -29.38%, CCRN is not doing good in the industry: 68.00% of the companies in the same industry are doing better.
- The Return On Invested Capital of CCRN (0.54%) is worse than 63.00% of its industry peers.
- CCRN had an Average Return On Invested Capital over the past 3 years of 6.06%. This is below the industry average of 8.51%.
- The 3 year average ROIC (6.06%) for CCRN is well above the current ROIC(0.54%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -29.38% | ||
| ROIC | 0.54% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
1.3 Margins
- The Operating Margin of CCRN (0.24%) is worse than 63.00% of its industry peers.
- CCRN's Operating Margin has declined in the last couple of years.
- With a Gross Margin value of 20.26%, CCRN perfoms like the industry average, outperforming 47.00% of the companies in the same industry.
- CCRN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.24% | ||
| PM (TTM) | N/A | ||
| GM | 20.26% |
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
2. CCRN Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CCRN is destroying value.
- Compared to 1 year ago, CCRN has less shares outstanding
- CCRN has less shares outstanding than it did 5 years ago.
- There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- CCRN has an Altman-Z score of 4.84. This indicates that CCRN is financially healthy and has little risk of bankruptcy at the moment.
- CCRN's Altman-Z score of 4.84 is amongst the best of the industry. CCRN outperforms 86.00% of its industry peers.
- There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.84 |
ROIC/WACC0.06
WACC8.9%
2.3 Liquidity
- A Current Ratio of 3.78 indicates that CCRN has no problem at all paying its short term obligations.
- CCRN has a better Current ratio (3.78) than 87.00% of its industry peers.
- CCRN has a Quick Ratio of 3.78. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.78, CCRN belongs to the top of the industry, outperforming 89.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.78 |
3. CCRN Growth Analysis
3.1 Past
- The earnings per share for CCRN have decreased strongly by -95.56% in the last year.
- CCRN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.59% yearly.
- Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -21.56% in the last year.
- Measured over the past years, CCRN shows a small growth in Revenue. The Revenue has been growing by 4.74% on average per year.
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
3.2 Future
- Based on estimates for the next years, CCRN will show a very strong growth in Earnings Per Share. The EPS will grow by 175.50% on average per year.
- Based on estimates for the next years, CCRN will show a small growth in Revenue. The Revenue will grow by 0.18% on average per year.
EPS Next Y455.34%
EPS Next 2Y271.84%
EPS Next 3Y175.5%
EPS Next 5YN/A
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. CCRN Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 493.00, the valuation of CCRN can be described as expensive.
- 60.00% of the companies in the same industry are cheaper than CCRN, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 27.87, CCRN is valued quite expensively.
- The Price/Forward Earnings ratio is 88.77, which means the current valuation is very expensive for CCRN.
- The rest of the industry has a similar Price/Forward Earnings ratio as CCRN.
- The average S&P500 Price/Forward Earnings ratio is at 38.51. CCRN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 493 | ||
| Fwd PE | 88.77 |
4.2 Price Multiples
- CCRN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CCRN is cheaper than 69.00% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, CCRN is valued cheaper than 86.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.92 | ||
| EV/EBITDA | 10.85 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as CCRN's earnings are expected to grow with 175.50% in the coming years.
PEG (NY)1.08
PEG (5Y)N/A
EPS Next 2Y271.84%
EPS Next 3Y175.5%
5. CCRN Dividend Analysis
5.1 Amount
- CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CCRN Fundamentals: All Metrics, Ratios and Statistics
9.86
-0.03 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-04 2026-03-04/amc
Earnings (Next)05-05 2026-05-05/amc
Inst Owners83.99%
Inst Owner Change0.01%
Ins Owners7.09%
Ins Owner Change17.24%
Market Cap317.49M
Revenue(TTM)1.05B
Net Income(TTM)-94.85M
Analysts74.67
Price Target11.9 (20.69%)
Short Float %4.28%
Short Ratio2.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-157.94%
Min EPS beat(2)-296.08%
Max EPS beat(2)-19.79%
EPS beat(4)1
Avg EPS beat(4)-107.17%
Min EPS beat(4)-296.08%
Max EPS beat(4)5.59%
EPS beat(8)3
Avg EPS beat(8)-61.22%
EPS beat(12)6
Avg EPS beat(12)-39.22%
EPS beat(16)10
Avg EPS beat(16)-25.76%
Revenue beat(2)0
Avg Revenue beat(2)-9.09%
Min Revenue beat(2)-9.46%
Max Revenue beat(2)-8.72%
Revenue beat(4)0
Avg Revenue beat(4)-7.87%
Min Revenue beat(4)-9.46%
Max Revenue beat(4)-5.84%
Revenue beat(8)0
Avg Revenue beat(8)-4.22%
Revenue beat(12)2
Avg Revenue beat(12)-2.78%
Revenue beat(16)5
Avg Revenue beat(16)-1.59%
PT rev (1m)2.55%
PT rev (3m)1.87%
EPS NQ rev (1m)-23.8%
EPS NQ rev (3m)-388.87%
EPS NY rev (1m)13.77%
EPS NY rev (3m)-7.98%
Revenue NQ rev (1m)-0.3%
Revenue NQ rev (3m)-7.76%
Revenue NY rev (1m)-3.67%
Revenue NY rev (3m)-3.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 493 | ||
| Fwd PE | 88.77 | ||
| P/S | 0.3 | ||
| P/FCF | 7.92 | ||
| P/OCF | 6.58 | ||
| P/B | 0.98 | ||
| P/tB | 1.37 | ||
| EV/EBITDA | 10.85 |
EPS(TTM)0.02
EY0.2%
EPS(NY)0.11
Fwd EY1.13%
FCF(TTM)1.25
FCFY12.63%
OCF(TTM)1.5
OCFY15.2%
SpS32.74
BVpS10.03
TBVpS7.19
PEG (NY)1.08
PEG (5Y)N/A
Graham Number2.12403 (-78.46%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -29.38% | ||
| ROCE | 0.68% | ||
| ROIC | 0.54% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 1.17% | ||
| OM | 0.24% | ||
| PM (TTM) | N/A | ||
| GM | 20.26% | ||
| FCFM | 3.8% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
ROICexc(3y)6.35%
ROICexc(5y)14.73%
ROICexgc(3y)10.08%
ROICexgc(5y)21.91%
ROCE(3y)7.68%
ROCE(5y)18.37%
ROICexgc growth 3Y-70.95%
ROICexgc growth 5Y-31.89%
ROICexc growth 3Y-71.51%
ROICexc growth 5Y-28.12%
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
F-Score6
Asset Turnover2.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 48.59% | ||
| Cap/Sales | 0.77% | ||
| Interest Coverage | 1.82 | ||
| Cash Conversion | 249.59% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 4.84 |
F-Score6
WACC8.9%
ROIC/WACC0.06
Cap/Depr(3y)57.55%
Cap/Depr(5y)63.04%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
EPS Next Y455.34%
EPS Next 2Y271.84%
EPS Next 3Y175.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5YN/A
EBIT growth 1Y103.69%
EBIT growth 3Y-79.18%
EBIT growth 5Y-28.09%
EBIT Next Year307.2%
EBIT Next 3Y80.75%
EBIT Next 5YN/A
FCF growth 1Y-64.01%
FCF growth 3Y-31.6%
FCF growth 5Y12.15%
OCF growth 1Y-59.83%
OCF growth 3Y-28.87%
OCF growth 5Y12.15%
CROSS COUNTRY HEALTHCARE INC / CCRN Fundamental Analysis FAQ
What is the ChartMill fundamental rating of CROSS COUNTRY HEALTHCARE INC (CCRN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CCRN.
What is the valuation status for CCRN stock?
ChartMill assigns a valuation rating of 4 / 10 to CROSS COUNTRY HEALTHCARE INC (CCRN). This can be considered as Fairly Valued.
What is the profitability of CCRN stock?
CROSS COUNTRY HEALTHCARE INC (CCRN) has a profitability rating of 2 / 10.
What is the valuation of CROSS COUNTRY HEALTHCARE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CROSS COUNTRY HEALTHCARE INC (CCRN) is 493 and the Price/Book (PB) ratio is 0.98.
Can you provide the financial health for CCRN stock?
The financial health rating of CROSS COUNTRY HEALTHCARE INC (CCRN) is 9 / 10.